What happened with MAZE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Maze Therapeutics uses human genetic information to find drug targets and develop small-molecule medicines for specific patient groups. Its Compass platform studies how genetic differences raise disease risk or protect against disease, then guides drug discovery and clinical-trial design. Its wholly owned clinical programs are MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease.
Maze has no approved products and has never generated product-sales revenue. Other drug companies pay it for rights to develop and commercialize selected programs. Shionogi’s upfront payment for MZE001, a Pompe disease candidate, supplied most of Maze’s licensing revenue to date. That agreement also provides for payments when development, regulatory or sales milestones are reached, and royalties on any eventual sales. Equity and debt financing, alongside upfront licensing payments, have funded operations.
The business depends on moving experimental medicines through clinical trials and obtaining regulatory approval before they can be sold. Income from licensed programs also depends on partners advancing and commercializing them; Maze has limited control over the resources and timing those partners commit.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Maze’s results hinge on its kidney and metabolic clinical programs and on Shionogi’s progress with licensed MZE001, which could bring substantial milestone payments and future sales royalties.
Vertex’s Phase 3 program for APOL1-mediated kidney disease directly competes with Maze’s clinical-stage MZE829 for the same patients. Vertex sells medicines through specialty pharmacies and distributors; its APOL1 study’s interim data, expected in 2026 based on publicly available information, are the readout to watch against MZE829.
Ionis and AstraZeneca’s AZD2373 targets APOL1 in the same kidney disease as Maze’s MZE829, making its clinical progress a competing benchmark. Ionis develops medicines that alter gene activity by targeting RNA or DNA and markets drugs itself and through partners; AZD2373’s development is the part to watch for Maze.
PTC already earns revenue from Sephience for phenylketonuria (PKU), the patient group Maze’s MZE782 could compete to treat. PTC sells rare-disease medicines, so Sephience sales—not its broader portfolio—are the relevant line to watch as MZE782 develops.
BioMarin already sells PALYNZIQ and KUVAN for PKU, putting Maze’s MZE782 up against established treatments for those patients. Sales of these two medicines, rather than BioMarin’s total revenue, show the existing PKU business that MZE782 would enter.
Agios’s AG-181 and Maze’s MZE782 are competing development programs for PKU patients. Agios’s marketed medicines treat adult pyruvate kinase deficiency and thalassemia, so AG-181 development news—not sales of those blood-disease treatments—is the relevant comparison for Maze.
Travere’s treatments for disease of the kidney’s filtering structures serve patients who overlap with Maze’s APOL1 program, but use different therapeutic approaches. Travere sells rare kidney and metabolic disease medicines; watch FILSPARI, its once-daily oral medicine that targets glomerular injury by blocking endothelin-1 and angiotensin II pathways.
Neurocrine took exclusive rights to Maze’s ATXN2 program, so successful development and commercialization could bring Maze milestone payments and royalties on future sales. Neurocrine sells medicines through specialty pharmacy and distribution networks; ATXN2’s development, regulatory and commercial achievements are what could trigger further payments to Maze.
Sanofi already sells treatments that replace an enzyme for Pompe disease, where Maze’s Shionogi-licensed MZE001 is in Phase 2 development. Sanofi’s Pompe treatment business is the competitive reference for MZE001, whose development and future sales could generate milestone payments and royalties for Maze.
BioMarin Pharmaceuticals Inc earningsBMRN
BioMarin’s report will show, through PALYNZIQ and KUVAN sales, how established the PKU treatment market is that Maze’s MZE782 could enter.
Watch sales of PALYNZIQ and KUVAN, not BioMarin’s total revenue. Steady or rising sales would show continued use of established PKU treatments and a mature set of options for MZE782 to compete with. Weakening sales could indicate limits to uptake, but would not show that patients will switch to MZE782. The takeaway is how active the existing treatment market is and what competitive bar Maze may face.
Fed Interest Rate Decision
Maze’s Fed rate decision matters because it can change the interest it pays on its Prime Rate-linked Hercules loan and the interest it earns on cash and marketable securities.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest costs on Maze’s Hercules loan as it reprices, while potentially increasing interest earned on its cash and marketable securities; the net effect depends on which change is larger.
If it comes in below expectations
Lower rates can reduce interest costs on Maze’s Hercules loan as it reprices, while potentially reducing interest earned on its cash and marketable securities; the net effect depends on which change is larger.
Travere Therapeutics, Inc. earningsTVTX
Travere Therapeutics’ report will show, through FILSPARI sales and uptake, how the kidney-treatment market is developing among patients who overlap with Maze’s APOL1 program.
Read FILSPARI sales alongside Travere’s comments on patient uptake. Stronger sales would show that patients in an overlapping kidney-disease population are using a treatment that works through a different approach; weaker sales could point to adoption or market-access hurdles. Neither result directly establishes demand for MZE829, which targets APOL1. The takeaway is whether this overlapping patient market shows treatment uptake, not whether MZE829 itself will succeed.
Sanofi earningsSNY
Sanofi’s report will show how its Pompe disease treatment business is doing, giving context for the market that MZE001, licensed by Maze to Shionogi, could enter.
If Sanofi reports sales or demand trends for its Pompe treatments, read them as evidence of how established enzyme-replacement therapies are doing in this market. Steady or rising sales would indicate continued patient demand and a mature competitor for MZE001; weaker sales could point to adoption or market-growth challenges, but would not show that MZE001 can replace those treatments. Sanofi’s results do not themselves trigger milestone or royalty payments to Maze. The takeaway is the market bar MZE001 could face.
Vertex Pharmaceuticals Inc earningsVRTX
If Vertex’s report updates its APOL1 kidney-disease trial data or progress, it will show how far its program competing with Maze’s MZE829 for the same patients has advanced.
If Vertex discloses APOL1 program data in its report or related update, look at the results, safety and trial progress together. Encouraging results or faster progress would make Vertex a stronger competitor for the same patients and raise the bar for MZE829; disappointing results or delays would ease that competitive pressure, but would not prove MZE829 works. The takeaway is whether Vertex is building a more advanced competing option.
Maze Therapeutics, Inc. earningsThis company
Maze Therapeutics’ report will show how research spending and license income affect the funding it has to advance its kidney and metabolic disease programs.
Read operating cash use and the balance of cash, cash equivalents and marketable securities alongside research spending and license revenue. Revenue recognition does not necessarily happen when a payment arrives. If cash use stays controlled and the Shionogi milestone adds funding, Maze has more room to advance MZE829 and MZE782; if spending rises without comparable funds coming in, pressure on its resources increases. The question is whether its available capital can support continued development.
